Merck is close to a $1.3 billion deal to buy Eyebiotech, whose lead drug, Restoret, is in development to treat eye conditions including a form of age-related macular degeneration.
Merck is close to a $1.3 billion deal to buy Eyebiotech, whose lead drug, Restoret, is in development to treat eye conditions including a form of age-related macular degeneration.